Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PGD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: PGD. Displaying page 1 of 1.
    EudraCT Number: 2013-000716-21 Sponsor Protocol Number: AP301-III-001 Start Date*: 2013-06-11
    Sponsor Name:Apeptico Forschung und Entwicklung GmbH
    Full Title: Pilot study to investigate the clinical effect of orally inhaled AP301 on treatment of primary graft dysfunction (PGD) in mechanically ventilated patients after primary lung transplantation
    Medical condition: Primary Graft Dysfunction (PGD) after lung transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003975-23 Sponsor Protocol Number: IGX1-ENT-XS-16-01 Start Date*: 2020-04-20
    Sponsor Name:Asherman Therapy S.L.U.
    Full Title: Efficacy and safety of autologous, mobilized, non-expanded CD133+ cells to treat Asherman´s Syndrome: A prospective, multi-center, phase I/II clinical trial.
    Medical condition: Asherman's syndrome also known as intrauterine synechiae
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038604 - Reproductive system and breast disorders 10053868 Asherman's syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004137-27 Sponsor Protocol Number: ScanCLAD_1.0(formerVersion_0.1) Start Date*: 2016-05-19
    Sponsor Name:Transplantationscentrum, Sahlgrenska Universitetssjukhuset
    Full Title: A Scandinavian controlled, randomized, open-label, and multi-centre study evaluating if once-daily tacrolimus or twice-daily cyclosporin, reduces the 3-year incidence of chronic lung allograft dysf...
    Medical condition: Recipients of primary bilateral lung transplant allograft
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004848-30 Sponsor Protocol Number: 12.12.2019 Start Date*: 2020-01-31
    Sponsor Name:Rigshospitalet
    Full Title: A Danish, single centre, double-blind, randomized study evaluating allogeneic adipose tissue derived mesenchymal stromal cell therapy to reduce primary graft dysfunction after lung transplantation....
    Medical condition: Lung transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066204 Chronic lung disease of prematurity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003331-32 Sponsor Protocol Number: AZI003 Start Date*: 2013-06-18
    Sponsor Name:KULeuven and University Hospitals Leuven
    Full Title: A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PRE-TRANSPLANT AND PROMPT POST-TRANSPLANT TREATMENT WITH AZITHROMYCIN TO IMPROVE EARLY ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTA...
    Medical condition: EARLY LUNG ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10050437 Prophylaxis against heart and lung transplant rejection LLT
    14.1 10022891 - Investigations 10016547 FEV LLT
    14.1 10042613 - Surgical and medical procedures 10050433 Prophylaxis against lung transplant rejection LLT
    14.1 10022891 - Investigations 10006414 Bronchial biopsy abnormal LLT
    14.1 10022891 - Investigations 10025041 Lung biopsy abnormal LLT
    14.1 10022891 - Investigations 10016549 FEV 1 abnormal LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    14.1 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    14.1 10021428 - Immune system disorders 10049237 Acute cellular rejection LLT
    14.1 10021428 - Immune system disorders 10066543 Acute allograft rejection LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039008 Reversible airways obstruction NOS LLT
    14.1 10021428 - Immune system disorders 10019319 Heart-lung transplant rejection PT
    14.1 10022891 - Investigations 10016550 FEV 1 decreased LLT
    14.1 10022891 - Investigations 10057799 Computerised tomogram thorax abnormal PT
    14.1 10022891 - Investigations 10063078 Bronchoalveolar lavage abnormal PT
    14.1 10042613 - Surgical and medical procedures 10056409 Heart and lung transplant PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068956 Respiratory tract inflammation PT
    14.1 100000004862 10049083 Respiratory tract infection NOS LLT
    14.1 10022891 - Investigations 10016553 FEV 1 low LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003204-39 Sponsor Protocol Number: BT–L-CsA–301–SLT Start Date*: 2019-01-09
    Sponsor Name:BREATH Therapeutics Inc.
    Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003205-25 Sponsor Protocol Number: BT–L-CsA–302–DLT Start Date*: 2019-01-09
    Sponsor Name:BREATH Therapeutics Inc.
    Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) AT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:33:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA